Stereotaxis (STXS) Receives European Approval for Additional Magnetic Irrigated Catheter
More News related to STXS
- Stereotaxis (STXS) Posts Q3 Loss of $0.14, Beats By 4c; Guides
- Stereotaxis Reports 26% Third Quarter 2009 Revenue Growth
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Stereotaxis (STXS) Receives European Approval for Additional Magnetic Irrigated Catheter
- Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
More News related to FDA
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
Stereotaxis (Nasdaq: STXS) received notice that the Celsius RMT ThermoCool catheter has received CE Mark for distribution in the European market. The product is the fifth advanced ablation catheter resulting from the on-going co-development agreement between Stereotaxis and Biosense Webster to design and distribute magnetically enabled catheters for use in the Niobe Magnetic Navigation System (MNS).
This catheter fills out the family of magnetic irrigated catheters to offer both localized and non-localized technology. Localized catheters are used for more complex arrhythmias requiring 3D electro-anatomic mapping for precise diagnosis, whereas non-localized catheters are typically used for simpler arrhythmias which can be treated using basic imaging and ECG recordings.
A pre-market approval (PMA) application supplement for the Celsius RMT ThermoCool catheter was submitted to the U.S. Food and Drug Administration in September.
[SM]
Related Categories
FDAStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
